CIK 0001395937 · Large accelerated filer
Syndax Pharmaceuticals Inc
Sign in to watch- Ticker
- SNDX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 320162505
- Phone
- 781-419-1400
- Business address
- 730 THIRD AVENUE, 9TH FLOOR, NEW YORK, NY, 10017
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $113,716
- in 1 filing, $114K under 10b5-1 plans
Net −$113,716. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2022-08-24 | Ordentlich Peter Chief Scientific Officer | Option exercise | +22,846 | $6.32 | $144K | 23,111 |
| 2022-08-24 | Ordentlich Peter Chief Scientific Officer | Sale | −22,846 | $25.04 | $572K | 265 |
| 2022-08-24 | Ordentlich Peter Chief Scientific Officer | Option exercise | +2,154 | $6.35 | $14K | 2,419 |
| 2022-08-24 | Ordentlich Peter Chief Scientific Officer | Sale | −2,154 | $25.04 | $54K | 265 |
| 2022-08-24 | Ordentlich Peter Chief Scientific Officer | Option exercise · Stock Options (Right to buy) | −2,154 | 0 | ||
| 2022-08-24 | Ordentlich Peter Chief Scientific Officer | Option exercise · Stock Options (Right to buy) | −22,846 | 0 | ||
| 2022-08-05 | Legault Pierre Director | Option exercise | +10,000 | $9.63 | $96K | 42,000 |
| 2022-08-05 | Legault Pierre Director | Sale | −10,000 | $23.02 | $230K | 32,000 |
| 2022-08-05 | Legault Pierre Director | Option exercise | +14,000 | $8.93 | $125K | 46,000 |
| 2022-08-05 | Legault Pierre Director | Sale | −14,000 | $23.02 | $322K | 32,000 |
| 2022-08-05 | Legault Pierre Director | Option exercise · Stock Options (Right to buy) | −10,000 | 0 | ||
| 2022-08-05 | Legault Pierre Director | Option exercise · Stock Options (Right to buy) | −14,000 | 0 | ||
| 2022-07-29 | Ordentlich Peter Chief Scientific Officer | Other acquisition | +265 | $14.12 | $4K | 265 |
| 2022-07-25 | Metzger Michael A Chief Executive Officer | Option exercise | +19,764 | $6.38 | $126K | 37,423 |
| 2022-07-25 | Metzger Michael A Chief Executive Officer | Sale | −19,764 | $21.06 | $416K | 17,659 |
| 2022-07-25 | Metzger Michael A Chief Executive Officer | Option exercise | +11,838 | $6.38 | $76K | 29,497 |
| 2022-07-25 | Metzger Michael A Chief Executive Officer | Sale | −11,838 | $21.06 | $249K | 17,659 |
| 2022-07-25 | Metzger Michael A Chief Executive Officer | Option exercise · Stock Options (Right to buy) | −19,764 | 0 | ||
| 2022-07-25 | Metzger Michael A Chief Executive Officer | Option exercise · Stock Options (Right to buy) | −11,838 | 0 | ||
| 2022-07-07 | Metzger Michael A Chief Executive Officer | Option exercise | +100 | $6.38 | $638 | 17,759 |
Page 13 of 15 · 290 trades